Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.7K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.7K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

17.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parkinson's disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications.

The Lancet. Neurology·2026
Same author

Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Recruitment strategies in a diverse Parkinson's disease cohort: lessons from the East London Parkinson's Disease Project.

BMJ neurology open·2026
Same author

Selection-guided discovery in South Asians implicates the MAPT locus in insulin resistance.

medRxiv : the preprint server for health sciences·2026
Same author

Sternum-worn vibrotactile device in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot trial.

NPJ Parkinson's disease·2026
Same author

The Multiple Sclerosis Severity Allele rs10191329<sup>A</sup> and Cognitive Function: A UK Biobank Study.

Annals of clinical and translational neurology·2026

Related Experiment Video

Updated: Dec 7, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.0K

Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosis.

Benjamin M Jacobs1,2, Thomas Taylor1,2, Amine Awad1,2

  • 1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, UK.

Brain Communications
|October 2, 2020
PubMed
Summary

This study identifies druggable genetic targets for multiple sclerosis (MS) by integrating genetic, methylation, and expression data. Findings prioritize genes for developing new MS therapies and preventive strategies.

Keywords:
Mendelian randomizationmultiple sclerosistherapeutics

More Related Videos

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.2K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.9K

Related Experiment Videos

Last Updated: Dec 7, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.0K
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.2K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.9K

Area of Science:

  • Genetics
  • Immunology
  • Pharmacogenomics

Background:

  • Multiple sclerosis (MS) is a complex autoimmune disease influenced by genetic and environmental factors.
  • Translating Genome-Wide Association Study (GWAS) findings into effective MS therapeutics and preventive strategies remains challenging.

Purpose of the Study:

  • To identify prioritized druggable genetic targets for multiple sclerosis (MS) by integrating multi-omic data.
  • To explore the potential for developing targeted preventive therapies for MS.

Main Methods:

  • Utilized summary-data-based Mendelian randomization to synthesize data from expression quantitative trait locus (eQTL), methylation quantitative trait locus (mQTL), and MS GWAS datasets.
  • Correlated methylation and expression data with MS susceptibility to prioritize genetic loci.
  • Integrated prioritized loci with druggable gene lists and analyzed protein-protein interactions and pathways using GeNets.
  • Conducted a systematic review of prioritized genes using the Open Targets platform to identify relevant clinical trials.

Main Results:

  • Identified 45 genes in peripheral blood associated with MS susceptibility, with 20 encoding proteins targeted by existing therapeutics.
  • Refined the list to 15 prioritized druggable target genes showing a link between methylation, expression, and MS.
  • Five of these 15 genes are targeted by existing drugs, and three (CD40, MERTK, PARP1) were replicated in an eQTL dataset.
  • Systematic review revealed early-phase trials targeting 13 of 20 prioritized genes in MS-related disorders.

Conclusions:

  • This study provides a prioritized list of druggable genetic targets for multiple sclerosis.
  • The findings offer a potential platform for developing targeted preventive therapies for MS.
  • Integration of multi-omic data and druggability assessment is a viable strategy for identifying novel therapeutic targets.